Related Topics News -

     
 Detail   |   Print 
     
《大行》大摩調整中生製藥2026至28年每股盈測 重申「增持」
2026-07-14T  
中生製藥獲國家藥監局受理TQB3454片新藥上市申請
2026-07-10T  
《大行》美銀證券重申中生製藥「買入」評級 目標價升至6.2元
2026-07-09T  
《大行》高盛:中生製藥或可達成更多授權交易 升目標價至8.41元
2026-07-09T  
中生製藥向阿斯利康授予TQC3721獨家許可 涉最多19億美元
2026-07-08T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.